nei THIS MONTH IN
PSYCHOPHARMACOLOGY
Do Anxiety Disorders During Pregnancy Increase Risk of Adverse Birth Outcomes?
October 13, 2017   

The decision to treat mental health conditions, such as anxiety disorders, during pregnancy is an important and personal one; the health of the mother must be carefully weighed against potential adverse outcomes to the fetus. A recently published study adds valuable data on which such decisions can be informed....
 Continue reading (Members only)
Cost-Effective Suicide Prevention Strategies
October 10, 2017   

A recent study examined the cost-effectiveness of three follow-up interventions intended for patients who screen positive for suicidality in the emergency department setting....
 Continue reading (Members only)
Extended-Release Oral Suspension Approved for ADHD
October 6, 2017   

The U.S. Food and Drug Administration (FDA) has approved a new extended-release medication for the treatment of attention deficit hyperactivity disorder (ADHD)....
 Continue reading
All Opioids Subject to REMS Requirements
October 3, 2017   

The U.S. Food and Drug Administration (FDA) announced it will broaden the existing Risk Evaluation and Mitigation Strategy (REMS)...
 Continue reading (Members only)
Perinatal Antidepressant Use and Psychiatric Disorders in Offspring
September 29, 2017   

A recent Danish cohort study examined the association between in utero exposure to antidepressants and risk of psychiatric disorders...
 Continue reading (Members only)
10% of US Children Have a Serious Emotional Disturbance
September 21, 2017   

A new meta-analysis of population-representative studies revealed that 10% of US children experience a serious emotional disturbance (SED) that is functionally impairing...
 Continue reading
FDA Permits Marketing of Mobile Medical Application for Substance Use Disorders
September 20, 2017   

The US FDA has permitted the marketing of the Reset device, the first mobile medical application to help treat substance use disorders...
 Continue reading
Meta-Analysis: What Treatments Are Safe and Effective in Pediatric Anxiety?
September 18, 2017   

A recent meta-analysis compared the effectiveness of cognitive behavioral therapy (CBT) and pharmacotherapy for childhood anxiety disorders...
 Continue reading (Members only)
New Mega-Analysis Supports Efficacy of Antidepressants in Adult Depression
September 12, 2017   

Recently, there has been much debate regarding the efficacy of antidepressants in the treatment of adults with major depressive disorder (MDD) due to the often-high levels of response to placebo in many clinical trials...
 Continue reading
SSRIs, SNRIs Show Small But Significant Benefit for Children and Adolescents With Common Mental Illnesses
September 11, 2017   

There continues to be much debate over the utility and risk-to-benefit ratio of antidepressant use within the pediatric population. In the present meta-analysis, Locher and colleagues investigated the safety and efficacy of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs)...
 Continue reading (Members only)
12345678910...
Top of Page